Enhanced circulating half-life and anti-tumor activity of a site-specific pegylated interferon- a protein therapeutic.
Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
Bioconjugate Chemistry 19: 299-305, 2008.
A long-acting, highly potent interferon α-2 conjugate created using site-specific PEGylation.
Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.
Bioconjugate Chemistry 16: 200-207, 2005.